May 24, 2018
Real-world evidence shows weight loss in people receiving Saxenda
People treated with Saxenda for weight management lost an average of 8.1 kg after six months in a real-world clinical…
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Novo Nordisk
March 23, 2018
Novo Nordisk’s type two diabetes treatment for adults approved in japan
The Japanese Ministry of Health, Labour and Welfare has approved Novo Nordisk’s treatment for type 2 diabetes adult patients, new…
February 28, 2018
Novo Nordisk files for regulatory approval in the US and the EU for treatment of haemophilia A
Novo Nordisk has submitted a Biologics License Applications (BLA) to the US Food and Drug Administration (FDA) and a Marketing…
February 22, 2018
Novo Nordisk wants to submit its new type 2 diabetes tablet in 2019, first phase trial hits aim
Novo Nordisk has completed the first phase 3a trial, PIONEER 1, with oral semaglutide, for treating type 2 diabetes in…
February 1, 2018
Novo Nordisk’s study shows reductions in blood sugar and weight compared with dulaglutide for type 2 diabetes, sales in diabetes, obesity increased
Novo Nordisk has published the results for semaglutide from a study aiming to test the treatment for type 2 diabetes.
January 8, 2018
Novo Nordisk in Ablynx €2.6 Billion buy
Novo Nordisk on Monday confirmed proposing on December 22, 2017 to acquire Ablynx for €28.00 per share in cash and…
December 7, 2017
Tresiba reduces hypoglycaemia regardless of blood sugar level
People with either type 1 or type 2 diabetes treated with Tresiba had fewer episodes of low blood sugar (hypoglycaemia) compared…
December 5, 2017
Switching to Tresiba benefits people with diabetes irrespective of blood sugar levels in a real-world setting
Switching to Tresiba from another basal insulin benefits people with diabetes regardless of whether or not their blood sugar levels…
October 16, 2017
The US Food and Drug Administration (FDA) has published the briefing documents ahead of the Advisory Committee meeting to discuss…
September 29, 2017
IDF and Novo Nordisk launch first-ever global survey on cardiovascular disease awareness among people with type 2 diabetes
To mark World Heart Day, the International Diabetes Federation (IDF) has partnered with Novo Nordisk to launch the first-ever multi-country online survey investigating the level of CVD awareness and knowledge among people living with type 2 diabetes.